| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05:18 | Why a Coding Agent May Emerge as a Key Unlock for Growth | ||
| Sa | Lilly's Taltz plus Zepbound shows efficacy in psoriatic arthritis trial | ||
| Sa | Biogen reports positive Phase 2 results for lupus skin drug | ||
| Sa | Priovant reports positive dermatomyositis trial results in NEJM | ||
| Sa | BofA previews Apple's first foldable iPhone | ||
| Sa | Alumis reports Phase 3 psoriasis trial results for envudeucitinib | ||
| Sa | Banco Comercial Português 2025 slides: net income tops €1B, ROE hits 14.1% | ||
| Sa | Nektar presents rezpegaldesleukin data at dermatology meeting | ||
| Sa | Sanofi reports positive phase 3 data for atopic dermatitis drug | ||
| Sa | Arcutis presents trial data on roflumilast cream for infants | ||
| Sa | Protagonist presents one-year data for psoriasis drug ICOTYDE | ||
| Sa | Maersk halts operations at Oman's Salalah port after security incident | ||
| Sa | Garanti BBVA agrees to sell Romanian unit for €591 million | ||
| Sa | Analyst compares Apple's strategy to what Samsung did in the past | ||
| Sa | Federal judge halts Nexstar-Tegna merger following antitrust challenge | ||
| Sa | Brava Q4 2025 slides: record production masks earnings disappointment | ||
| Sa | PubMatic Q4 2025 slides: 35% EBITDA margin amid AI transformation | ||
| Sa | EverCommerce Q4 2025 slides: AI push, revenue beat offset by earnings miss | ||
| Sa | Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially | ||
| Sa | BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio | ||
| Sa | Blend Labs Q4 2025 slides: revenue beats, margins expand amid EPS miss | ||
| Sa | Bapcor 1H26 slides: new CEO outlines turnaround after $105M loss | ||
| Sa | Cheniere Q4 2025 slides: record LNG exports drive 42% cash flow surge | ||
| Sa | Fundrise Innovation Fund faces steep reversal after explosive NYSE debut | ||
| Sa | KPMG UK moves to slash audit headcount as attrition rates plummet - Bloomberg |